SCA
BIOT

Salient Capital Advisors’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

Salient Capital Advisors’s Portfolio BIOT Stock Details BIOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-32,175
Closed -$317K – 88
2022
Q1 		$317K Hold
32,175
– – 0.01% 56
2021
Q4 		$317K Buy
+32,175
New +$316K 0.02% 63

Other funds holding BIOT

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CCP
Corbin Capital Partners New York $61.3M AUM 53.03% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
CM
Cohanzick Management Pleasantville, New York $231K AUM 3.17% 1-Year Est. Return
RA
RiverPark Advisors New York $219M AUM 14.89% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Salient Capital Advisors's BIOT Position: Q2 2022 in Review

Salient Capital Advisors sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q2 2022, closing a stake of 32,175 shares — an estimated $317K sold.

Salient Capital Advisors first reported a position in BIOT in Q4 2021 and held it in 2 quarters. The position peaked at $317K in Q1 2022. 67 funds tracked by Wall St. Rank hold BIOT as of Q2 2022.

  • Salient Capital Advisors reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q2 2022 after selling out during the quarter.
  • Salient Capital Advisors sold 32,175 Biotech Acquisition Company Class A Ordinary Shares shares in Q2 2022, an estimated $317K.
  • Salient Capital Advisors first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q4 2021 and held it in 2 quarters.
  • Salient Capital Advisors's Biotech Acquisition Company Class A Ordinary Shares position peaked at $317K in Q1 2022.
  • 67 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q2 2022.

Based on Salient Capital Advisors's 13F filing for Q2 2022, filed 2 Aug 2022.